The making of DNA

Enabling the genetic medicine revolution with our unique dbDNA™ technology.

How we make DNA
Platform Technology

dbDNA™:
Powering the genetic medicine revolution

Our novel, synthetic DNA vector, “doggybone” or dbDNA™, and its enzymatic production, enable us to make DNA at the speed, scale and purity necessary to support the rapid growth of genetic medicines.

Doggybone DNA animation
Enzyme

DNA made using enzymes

We are disrupting the decades-old technology of DNA production, moving away from restrictive biological approaches to instead use a synthetic DNA vector.

Our platform technology
Rapid icon
Rapid

Enzymatic manufacturing enables multi-gram GMP DNA production in weeks rather than months

Scalable icon
Scalable

Manufactured using benchtop equipment with a significantly smaller footprint than fermentation-based production

Mobile icon
Mobile

dbDNA™ technology is highly portable and amenable to technology transfer

Optimal vector icon
Optimal vector

dbDNA™ can encode long, complex, unstable sequences, eliminates bacterial sequences, and has a strong expression profile

Addressing a broad market

Our versatile dbDNA™ technology is being applied across the genetic medicine industry.

mRNA icon

mRNA

Find out more
Lentivirus

Lentivirus

Find out more
AAV icon

AAV

Find out more
Genome editing icon

Genome editing

Find out more
DNA vaccines icon

DNA vaccines

Find out more
Non viral gene therapy

Non-viral gene therapy

Find out more
Our Services

What can we do for you?

We offer a range of services to support development and commercialisation of the next generation of DNA products.

Pre-clinical services
Pre-clinical services
  • Catalogue products
  • Molecular biology
  • Custom research grade
  • Toxicology materials
Find out more
GMP Supply
GMP supply
  • GMP dbDNA™ (critical starting materials)
  • GMP dbDNA™ (drug substance)
  • Commercial supply / on-site supply
Find out more
Development Services
Development Services
  • Analytical development
  • Scale up development
  • Formulation
  • Stability
Find out more
Regulatory Support
Regulatory support
  • Regulatory support
Find out more
Our facilities

Headquartered in Hampton

Take a tour of our stunning buildings and state-of-the-art dbDNA™ manufacturing facilities.

View our facilities
Our programs and partners

Work with us to develop the next generation of DNA products

We are working in collaboration with esteemed partners, to leverage dbDNA™ in areas where it may offer unique or improved therapies or devices.

Find out more
Find out more

Knowledge Centre

New Touchlight Webinar, 30th November 2022. AAV Manufacturing — Overcoming the Challenges of Plasmid DNA. Speakers include Dr Lisa Caproni, Head of Vaccine Therapy, Touchlight and Dr Leszek Lisowski, Unit Head, Children's Medical Institute, University of Sydney provided to you by XTalks and Touchlight
Webinar – Overcoming the challenges of plasmid DNA in AAV manufacturing
Read Article
White paper on lentivirus manufacturing
Sarah Moore

Dr Sarah Moore

White Paper – The future of Industrial Scale Lentiviral Vector Manufacturing
Read Article
TOPRA article antibiotic resistance
Satish Muchakayala

Satish Muchakayala

Article – Antibiotics in biopharmaceutical production
Read Article
Strategies for commercialising a novel enzymatic technology
Webinar – Strategies for commercialising a novel enzymatic DNA technology
Read Article
mRNA production info sheet header
Info sheet – Enzymatic DNA for mRNA production
Download
MDPI publication - SARS CoV 2 doggybone DNA
Vaccines – SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model
Read Article
Knowledge centre

News

15 November 2022

Touchlight signs license agreement with Voyager for use of Touchlight’s DNA technology in Voyager’s capsid discovery platform

Hampton, UK, 15 November 2022 – Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a patent license agreement with Voyager Therapeutics, Inc., a gene...

26 September 2022

Touchlight awarded Innovate UK grant for the measurement and intracellular visualisation of synthetic DNA constructs

Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has been awarded an Innovate UK grant enabling it to work, alongside partners, at addressing the...

06 September 2022

Lonza and Touchlight collaborate on end-to-end mRNA offering

Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNA).  Touchlight provides synthetic DNA through a cell-free enzymatic process, with...
All news
Contact us

We'd like to hear from you

For more information on how our dbDNA™ technology could help advance your project, please contact us.

Get in touch